T A Pollak1, S De Simoni2, B Barimani3, F O Zelaya4, J M Stone4, M A Mehta4. 1. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's Health Partners, King's College London, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK. thomas.pollak@kcl.ac.uk. 2. Computational, Cognitive and Clinical Neuroimaging Laboratory, Department of Medicine, Imperial College London, London, UK. 3. Faculty of Medicine, Imperial College London, London, UK. 4. Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Abstract
RATIONALE: The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine provides a pragmatic approach to address the link between glutamate-mediated changes in brain function and psychosis-like experiences. Most studies using PET or BOLD fMRI have assessed these symptoms broadly, which may limit inference about specific mechanisms. OBJECTIVES: The objective of this study is to identify the cerebral blood flow (CBF) correlates of ketamine-induced psychopathology, focusing on individual psychotomimetic symptom dimensions, which may have separable neurobiological substrates. METHODS: We measured validated psychotomimetic symptom factors following intravenous ketamine administration in 23 healthy male volunteers (10 given a lower dose and 13 a higher dose) and correlated ketamine-induced changes in symptoms with regional changes in CBF, measured non-invasively using arterial spin labelling (ASL). RESULTS: The main effect of ketamine paralleled previous studies, with increases in CBF in anterior and subgenual cingulate cortex and decreases in superior and medial temporal cortex. Subjective effects were greater in the high-dose group. For this group, ketamine-induced anhedonia inversely related to orbitofrontal cortex CBF changes and cognitive disorganisation was positively correlated with CBF changes in posterior thalamus and the left inferior and middle temporal gyrus. Perceptual distortion was correlated with different regional CBF changes in the low- and high-dose groups. CONCLUSIONS: Here, we provide evidence for the sensitivity of ASL to the effects of ketamine and the strength of subjective experience, suggesting plausible neural mechanisms for ketamine-induced anhedonia and cognitive disorganisation.
RATIONALE: The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine provides a pragmatic approach to address the link between glutamate-mediated changes in brain function and psychosis-like experiences. Most studies using PET or BOLD fMRI have assessed these symptoms broadly, which may limit inference about specific mechanisms. OBJECTIVES: The objective of this study is to identify the cerebral blood flow (CBF) correlates of ketamine-induced psychopathology, focusing on individual psychotomimetic symptom dimensions, which may have separable neurobiological substrates. METHODS: We measured validated psychotomimetic symptom factors following intravenous ketamine administration in 23 healthy male volunteers (10 given a lower dose and 13 a higher dose) and correlated ketamine-induced changes in symptoms with regional changes in CBF, measured non-invasively using arterial spin labelling (ASL). RESULTS: The main effect of ketamine paralleled previous studies, with increases in CBF in anterior and subgenual cingulate cortex and decreases in superior and medial temporal cortex. Subjective effects were greater in the high-dose group. For this group, ketamine-induced anhedonia inversely related to orbitofrontal cortex CBF changes and cognitive disorganisation was positively correlated with CBF changes in posterior thalamus and the left inferior and middle temporal gyrus. Perceptual distortion was correlated with different regional CBF changes in the low- and high-dose groups. CONCLUSIONS: Here, we provide evidence for the sensitivity of ASL to the effects of ketamine and the strength of subjective experience, suggesting plausible neural mechanisms for ketamine-induced anhedonia and cognitive disorganisation.
Authors: S De Simoni; A J Schwarz; O G O'Daly; A F Marquand; C Brittain; C Gonzales; S Stephenson; S C R Williams; M A Mehta Journal: Neuroimage Date: 2012-09-23 Impact factor: 6.556
Authors: Robin L Carhart-Harris; David Erritzoe; Tim Williams; James M Stone; Laurence J Reed; Alessandro Colasanti; Robin J Tyacke; Robert Leech; Andrea L Malizia; Kevin Murphy; Peter Hobden; John Evans; Amanda Feilding; Richard G Wise; David J Nutt Journal: Proc Natl Acad Sci U S A Date: 2012-01-23 Impact factor: 11.205
Authors: Rowena Handley; Fernando O Zelaya; A A T Simone Reinders; Tiago Reis Marques; Mitul A Mehta; Ruth O'Gorman; David C Alsop; Heather Taylor; Atholl Johnston; Steve Williams; Philip McGuire; Carmine M Pariante; Shitij Kapur; Paola Dazzan Journal: Hum Brain Mapp Date: 2012-03-25 Impact factor: 5.038
Authors: Stephanie B Stewart; Jonathan M Koller; Meghan C Campbell; Joel S Perlmutter; Kevin J Black Journal: PeerJ Date: 2015-03-17 Impact factor: 2.984
Authors: James M Stone; Fiona Pepper; Johnson Fam; Hannah Furby; Emer Hughes; Celia Morgan; Oliver D Howes Journal: Psychopharmacology (Berl) Date: 2013-11-22 Impact factor: 4.530
Authors: Mitul A Mehta; Anne Schmechtig; Vasileia Kotoula; Juliet McColm; Kimberley Jackson; Claire Brittain; Sitra Tauscher-Wisniewski; Bruce J Kinon; Paul D Morrison; Thomas Pollak; Timothy Mant; Steven C R Williams; Adam J Schwarz Journal: Psychopharmacology (Berl) Date: 2018-03-21 Impact factor: 4.530
Authors: James Edward Bryant; Michael Frölich; Steve Tran; Meredith Amanda Reid; Adrienne Carol Lahti; Nina Vanessa Kraguljac Journal: J Psychiatr Res Date: 2019-07-27 Impact factor: 4.791
Authors: M Steffens; C Neumann; A-M Kasparbauer; B Becker; B Weber; M A Mehta; R Hurlemann; U Ettinger Journal: Psychopharmacology (Berl) Date: 2018-10-24 Impact factor: 4.530
Authors: M Steffens; B Becker; C Neumann; A M Kasparbauer; I Meyhöfer; B Weber; M A Mehta; R Hurlemann; U Ettinger Journal: Hum Brain Mapp Date: 2016-11 Impact factor: 5.038
Authors: Leah M Fleming; Daniel C Javitt; Cameron S Carter; Joshua T Kantrowitz; Ragy R Girgis; Lawrence S Kegeles; John D Ragland; Richard J Maddock; Tyler A Lesh; Costin Tanase; James Robinson; William Z Potter; Marlene Carlson; Melanie M Wall; Tse-Hwei Choo; Jack Grinband; Jeffrey Lieberman; John H Krystal; Philip R Corlett Journal: Neuroimage Clin Date: 2019-02-28 Impact factor: 4.881
Authors: Lise Vlerick; Kathelijne Peremans; Robrecht Dockx; Kurt Audenaert; Chris Baeken; Bart De Spiegeleer; Jimmy Saunders; Ingeborgh Polis Journal: PLoS One Date: 2018-12-18 Impact factor: 3.240
Authors: Grant McQueen; John Lally; Tracy Collier; Fernando Zelaya; David J Lythgoe; Gareth J Barker; James M Stone; Philip McGuire; James H MacCabe; Alice Egerton Journal: Psychopharmacology (Berl) Date: 2018-08-23 Impact factor: 4.530